Case Study: Leading Global Pharmaceutical Company achieves 14-week faster enrollment (44% timeline reduction) with IQVIA

Psoriasis Enrollment Completed 14 Weeks Ahead of Schedule

A Leading Global Pharmaceutical Company running a Phase III psoriasis study engaged IQVIA (via IQVIA Biotech) to address slow site enrollment and meet the sponsor’s goal of randomizing 1,152 patients within nine months. The key challenge was overcoming site enrollment delays that risked extending the development timeline and increasing costs.

IQVIA implemented its patient recruitment process and predictive enrollment methodology, launching a national, site‑tailored advertising campaign concentrated in the first three months and adjusting tactics through regular enrollment metric analysis. The result: enrollment completed in 18 weeks (1,152 patients), 14 weeks ahead of schedule—a 44% reduction in timeline versus the projected 32 weeks—IQVIA delivered 62% of enrolled patients, and the study stayed on budget.